Methylphenidate Dosing: Twice Daily Versus Three Times Daily

¹ Department of Psychiatry, University of Chicago, Chicago, Illinois; Department of Pediatrics, University of Chicago, Chicago, Illinois
² Department of Pediatrics, University of Chicago, Chicago, Illinois
³ Private Practice-Pediatric Neurology, Hoffman Estates, Illinois
⁴ Department of Psychiatry, University of Chicago, Chicago, Illinois
⁵ Lutheran General Hospital Pharmacy, Des Plaines, Illinois

Objective. To evaluate the short-term efficacy and side effects associated with two methylphenidate hydrochloride (MPH) dosing patterns.

Methods. Twenty-five boys with attention deficit hyperactivity disorder (ADHD) participated in a 5-week, triple-blind, placebo-controlled, crossover evaluation of MPH administered twice (b.i.d.) versus thrice (t.i.d.) per day (mean dose 8.8 ± 5 mg, .30 ± .1 mg/kg/dose). Four dosing conditions (placebo, titration [gradual increase to target dose], b.i.d., and t.i.d.) were used. Dependent measures obtained on a weekly basis included: parent and teacher ratings of child behavior, parent-child conflicts, parent report of stimulant side effects, child self-report of mood symptoms, a sleep log, laboratory measures of attention, and actigraphic recording of sleep activity.

Results. All dosing conditions resulted in significant effects on ADHD symptoms when compared with baseline. Relative to placebo, t.i.d. dosing was characterized by improvement on the greatest number of behavioral measures, and both b.i.d. and t.i.d. were generally more effective than titration. Direct comparisons of b.i.d. and t.i.d. dosing revealed that t.i.d. was associated with greater improvement on the Conners Parent Rating Scale Impulsivity/Hyperactivity factor, with a similar marginally significant effect for the ADD-H Teacher Rating Scale Hyperactivity factor. The analysis of clinically significant change favored a three-times-a-day dosing schedule over placebo on both parent and teacher ratings of impulsivity/hyperactivity and attention. Compared with placebo, appetite suppression was rated, on average, as more severe in the t.i.d. and titration conditions, but not in the b.i.d condition. However, the number of subjects who exhibited any or severe appetite suppression did not differ significantly between the b.i.d. and t.i.d. schedules. Although there was no difference in sleep duration for children on b.i.d. and t.i.d. schedules, total sleep time appeared to decrease slightly on t.i.d. relative to placebo according to both parent ratings and actigraphic assessment. There were no significant differences between b.i.d. and t.i.d. on any other side effects or sleep variables.

Conclusions. For many children with ADHD, t.i.d. dosing may be optimal. There are few differences in acute side effects between b.i.d and t.i.d. MPH dosing. The dosing schedule should be selected according to the severity and time course of ADHD symptoms rather than in anticipation of dosing schedule-related side effects.

This article has been cited by other articles:

				P. Corkum, R. Panton, S. Ironside, M. MacPherson, and T. Williams Acute Impact of Immediate Release Methylphenidate Administered Three Times a Day on Sleep in Children with Attention-Deficit/Hyperactivity Disorder J. Pediatr. Psychol., May 1, 2008; 33(4): 368 - 379. [Abstract] [Full Text] [PDF]

				A. P. Aldenkamp, A. Arzimanoglou, R. Reijs, and S. Van Mil Optimizing therapy of seizures in children and adolescents with ADHD Neurology, December 26, 2006; 67(12_suppl_4): S49 - S51. [Abstract] [Full Text]

				T. E. Wilens, K. McBurnett, O. Bukstein, J. McGough, L. Greenhill, M. Lerner, M. A. Stein, C. K. Conners, J. Duby, J. Newcorn, et al. Multisite Controlled Study of OROS Methylphenidate in the Treatment of Adolescents With Attention-Deficit/Hyperactivity Disorder Arch Pediatr Adolesc Med, January 1, 2006; 160(1): 82 - 90. [Abstract] [Full Text] [PDF]

				M Tan and R Appleton Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy Arch. Dis. Child., January 1, 2005; 90(1): 57 - 59. [Abstract] [Full Text] [PDF]

				D. K. Kelsey, C. R. Sumner, C. D. Casat, D. L. Coury, H. Quintana, K. E. Saylor, V. K. Sutton, J. Gonzales, S. K. Malcolm, K. J. Schuh, et al. Once-Daily Atomoxetine Treatment for Children With Attention-Deficit/Hyperactivity Disorder, Including an Assessment of Evening and Morning Behavior: A Double-Blind, Placebo-Controlled Trial Pediatrics, July 1, 2004; 114(1): e1 - e8. [Abstract] [Full Text] [PDF]

				M. A. Stein, C. S. Sarampote, I. D. Waldman, A. S. Robb, C. Conlon, P. L. Pearl, D. O. Black, K. E. Seymour, and J. H. Newcorn A Dose-Response Study of OROS Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder Pediatrics, November 1, 2003; 112(5): e404 - 404. [Abstract] [Full Text] [PDF]

				K. Gucuyener, A. K. Erdemoglu, S. Senol, A. Serdaroglu, S. Soysal, and I. Kockar Use of Methylphenidate for Attention-Deficit Hyperactivity Disorder in Patients With Epilepsy or Electroencephalographic Abnormalities J Child Neurol, February 1, 2003; 18(2): 109 - 112. [Abstract] [PDF]

				D. Stein, R. Pat-Horenczyk, S. Blank, Y. Dagan, Y. Barak, and T. P. Gumpel Sleep Disturbances in Adolescents with Symptoms of Attention-Deficit/Hyperactivity Disorder J Learn Disabil, May 1, 2002; 35(3): 268 - 275. [Abstract] [PDF]

				N. Purdie, J. Hattie, and A. Carroll A Review of the Research on Interventions for Attention Deficit Hyperactivity Disorder: What Works Best? Review of Educational Research, January 1, 2002; 72(1): 61 - 99. [Abstract] [PDF]

				B. Vitiello Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder Can. Med. Assoc. J., November 1, 2001; 165(11): 1505 - 1506. [Full Text] [PDF]

				D. Michelson, D. Faries, J. Wernicke, D. Kelsey, K. Kendrick, F. R. Sallee, T. Spencer, and the Atomoxetine ADHD Study Group Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study Pediatrics, November 1, 2001; 108(5): e83 - 83. [Abstract] [Full Text] [PDF]

				W. E. Pelham, E. M. Gnagy, L. Burrows-Maclean, A. Williams, G. A. Fabiano, S. M. Morrisey, A. M. Chronis, G. L. Forehand, C. A. Nguyen, M. T. Hoffman, et al. Once-a-Day Concerta Methylphenidate Versus Three-Times-Daily Methylphenidate in Laboratory and Natural Settings Pediatrics, June 1, 2001; 107(6): e105 - 105. [Abstract] [Full Text] [PDF]

				M. A. Kent, C. S. Camfield, and P. R. Camfield Double-blind Methylphenidate Trials: Practical, Useful, and Highly Endorsed by Families Arch Pediatr Adolesc Med, December 1, 1999; 153(12): 1292 - 1296. [Abstract] [Full Text] [PDF]

				W. E. Pelham, E. M. Gnagy, A. M. Chronis, L. Burrows-MacLean, G. A. Fabiano, A. N. Onyango, D. L. Meichenbaum, A. Williams, H. R. Aronoff, and R. L. Steiner A Comparison of Morning-Only and Morning/Late Afternoon Adderall to Morning-Only, Twice-Daily, and Three Times-Daily Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder Pediatrics, December 1, 1999; 104(6): 1300 - 1311. [Abstract] [Full Text]

				A. Ring, D. Stein, Y. Barak, A. Teicher, J. Hadjez, A. Elizur, and A. Weizman Sleep Disturbances in Children with Attention-Deficit/Hyperactivity Disorder: A Comparative Study with Healthy Siblings J Learn Disabil, November 1, 1998; 31(6): 572 - 578. [Abstract] [PDF]

				E. J. Garland Reviews : Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats J Psychopharmacol, January 1, 1998; 12(4): 385 - 395. [Abstract] [PDF]